GLP-1 Pills: The Oral Options, Explained

For years the honest answer to "is there a GLP-1 in pill form?" was one drug, one indication: Rybelsus, for type 2 diabetes. That answer is now out of date, and most of the pages ranking for this question still give it. Between December 2025 and April 2026 the FDA approved the first oral GLP-1 for weight management and the first small-molecule GLP-1 pill, and Novo Nordisk brought oral semaglutide to market under the Ozempic name. Four pills, two different label indications, two very different sets of rules for how you swallow them.

Is There a GLP-1 Pill? All Four, in One Table

Every product below is an oral tablet, prescription only, taken once daily. What separates them is the FDA-approved indication on the label. That distinction is not a technicality: it determines what the drug was studied for, what the manufacturer may promote it for, and whether a prescription for a different purpose is off-label.

Is Ozempic Available in Pill Form?

Yes. This is the part that has changed most recently and that most search results still get wrong. Novo Nordisk now markets Ozempic (semaglutide) tablets in 1.5 mg, 4 mg and 9 mg, and the company announced US availability starting May 4, 2026. It is oral semaglutide, the same molecule as the Ozempic pen, in a tablet.

What has not changed is the indication. Per the FDA label shared by Rybelsus and Ozempic tablets, the tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk. Weight loss is not an approved indication for the Ozempic pill any more than it is for the Ozempic pen. If you are looking for the semaglutide pill that FDA approved for weight, that is the Wegovy tablet, covered below.

The old misconception was that "Ozempic in pill form" did not exist. The new misconception is more dangerous: that because the Ozempic pill now exists, it is the weight-loss pill. It is not. If you want the full picture of which brand covers which use, our Wegovy vs Ozempic comparison and the full GLP-1 medications list lay out every brand and its approved indication side by side.

Rybelsus: The Original Semaglutide Tablet

Rybelsus was the first oral GLP-1 in the US and remains on the market in 3 mg, 7 mg and 14 mg tablets for type 2 diabetes. The Ozempic tablet strengths were designed to reach comparable drug exposure at a lower milligram number, which is why 1.5 mg, 4 mg and 9 mg map onto 3 mg, 7 mg and 14 mg rather than being lower doses in any meaningful sense. Novo Nordisk has stated that Rybelsus patients should continue their medication as directed and speak with their healthcare professional about transitioning to the Ozempic pill as appropriate.

The dosing schedule the FDA label specifies for Rybelsus is a fixed 30-day step-up. The label is explicit that the 3 mg starting dose is a tolerability step and is not effective for glycemic control on its own.

Semaglutide Tablets for Weight Loss: The Wegovy Pill

On December 22, 2025, the FDA approved the Wegovy pill, once-daily oral semaglutide, the first oral GLP-1 approved for weight management. The label indicates Wegovy tablets in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

The dose ladder the label specifies runs four steps over 90 days to a 25 mg maintenance dose, which is far higher than the diabetes tablets. The label also notes that if a patient does not tolerate a step, the prescriber may delay escalation, and that if the 25 mg maintenance dose is not tolerated, switching to the once-weekly injection is an option the prescriber can consider.

What the trial in the label showed. The 64-week randomized, double-blind, placebo-controlled trial reported in the label enrolled 307 adults with obesity or overweight plus at least one weight-related comorbidity; adults with type 2 diabetes were excluded. In the intention-to-treat analysis, mean body weight change at week 64 was -13.6% with the tablet versus -2.4% with placebo. 76.3% of tablet-treated patients lost at least 5% of body weight versus 31.3% on placebo, and 27.9% lost at least 20% versus 3.1% on placebo. Those are trial averages under trial conditions, not a promise about any individual.

Foundayo (Orforglipron): The Pill With No Food Rule

In April 2026 the FDA approved Foundayo (orforglipron) for chronic weight management: indicated with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. It is not approved for type 2 diabetes.

Orforglipron is chemically different from every GLP-1 that came before it. Semaglutide, tirzepatide and liraglutide are peptides. Orforglipron is a non-peptide small molecule, which is why its label allows it to be taken with or without food, at any time of day, with no water restriction. For anyone who has looked at the oral semaglutide rules and concluded they could never keep to them, that difference is the entire point of the drug.

The label specifies a starting dosage of 0.8 mg once daily, increasing to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 days, with further increases to 9 mg, 14.5 mg or 17.2 mg permitted after at least 30 days at the current dose, based on treatment response and tolerability. Maximum dosage is 17.2 mg once daily. Tablets are swallowed whole, never broken, crushed or chewed, and never more than one per day.

In the two 72-week placebo-controlled trials in the label, intention-to-treat mean weight change at week 72 in the trial that excluded type 2 diabetes was -7.4% at 5.5 mg, -8.3% at 9 mg and -11.1% at 17.2 mg, versus -2.1% on placebo. In the trial in adults with type 2 diabetes the corresponding figures were -5.1%, -7.0% and -9.6% versus -2.5% on placebo.

How Oral Semaglutide Has to Be Taken

Semaglutide is a peptide. Swallowed on its own it would be broken down before it was absorbed, so the tablets are co-formulated with an absorption enhancer called SNAC, and absorption happens predominantly in the stomach. That mechanism is the reason the administration rules are so specific, and why ignoring them undercuts the drug rather than just being inconvenient.

The FDA label states the same instructions for Wegovy tablets and for the Ozempic and Rybelsus tablets:

• Once daily, on an empty stomach, in the morning. One tablet, no more than one tablet per day.
• Water only, up to 4 ounces. The label says not to take the tablets with any other liquid besides water.
• Swallow whole. Do not split, crush, chew or dissolve the tablet in any solution.
• Wait at least 30 minutes before eating food, drinking beverages, or taking other oral medications.
• Missed dose: for Wegovy tablets the label says to skip the missed dose and take the next dose the following day.

Read that list as a daily-life constraint before you read it as a clinical one. It means no coffee for half an hour after the tablet, and it means other morning prescriptions get pushed back. Foundayo has none of those requirements. That is a real difference between two drugs that otherwise look interchangeable on a comparison chart.

GLP-1 Pill vs Injection

Adherence is the honest axis here. A weekly injection asks for one correct decision every seven days. A daily tablet with an empty-stomach window asks for one every morning. Which is easier is a personal question, not a clinical ranking. If you are weighing molecules rather than formats, our semaglutide vs tirzepatide comparison covers the injectable head-to-head, and the semaglutide dosing guide and tirzepatide dosing guide report the injection schedules the labels specify.

What GLP-1 Pills Cost Without Insurance

Every figure below is a manufacturer self-pay price published by the manufacturer itself. They carry eligibility conditions and expiry dates, and they are not what a pharmacy charges at list price.

Read the maintenance row, not the starter row. The self-pay entry price for oral semaglutide is a starting-dose price, and the Wegovy tablet ladder reaches its 25 mg maintenance dose on day 91. Budget the maintenance number, because that is the one you live with. For a wider comparison across both pills and injections, see the cheapest GLP-1 without insurance, verified semaglutide program prices and verified tirzepatide program prices.

Compounded Oral Semaglutide: What FDA Says

Compounded "oral semaglutide" is sold online as drops, sublingual troches and tablets. It is not the same category of product as anything above. Compounded drugs are not FDA approved. FDA states that unapproved versions do not undergo its review for safety, effectiveness and quality before they are marketed, and that a compounded drug might be appropriate only when a patient's medical need cannot be met by an FDA-approved drug.

• Dosing errors. FDA has received multiple reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded semaglutide, including patients and health care professionals miscalculating doses, and prescriptions written beyond what the approved label allows.
• Salt forms. FDA has said semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs, and that it is not aware of any lawful basis for their use in compounding.
• Volume of reports. As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and notes these are likely underreported.
• Fraudulent product. FDA has identified compounded semaglutide and tirzepatide sold with false label information, in some cases naming pharmacies that do not exist.

FDA also publishes telehealth red flags: claims that a compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, no screening or prescription by a licensed doctor, no clinician available afterward, and label misspellings or wrong pharmacy addresses. Our compounded semaglutide guide goes deeper on the legal status and the pricing, and our review of GLP-1 weight-loss programs covers which telehealth providers dispense FDA-approved product versus compounded.

Side Effects and Who Should Not Take These

All four pills carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Warnings across the labels include acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia when combined with insulin or an insulin secretagogue, hypersensitivity reactions, gallbladder disease, diabetic retinopathy complications in patients with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation. Tell any surgeon or anesthesiologist that you take a GLP-1.

Semaglutide tablets. The label lists the most common adverse reactions at an incidence of 5% or more for the type 2 diabetes tablets as nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation. For Wegovy, the most common reactions at 5% or more include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension and eructation. In the Wegovy tablet trial, 6.9% of tablet-treated patients discontinued because of adverse reactions versus 5.9% on placebo.

Foundayo. In the pooled placebo-controlled trials in the label, nausea was reported by 26% at 5.5 mg, 34% at 9 mg and 35% at 17.2 mg versus 10% on placebo; constipation by 20%, 27% and 24% versus 9%; diarrhea by 21%, 23% and 25% versus 11%; and vomiting by 13%, 21% and 24% versus 4%. The label notes that gastrointestinal reactions were highest during dose escalation and decreased over time, and that of patients reporting them, 60% were mild, 36% moderate and 4% severe.

Side-effect profiles by drug are covered in more depth in our Ozempic side effects guide and tirzepatide side effects guide. None of that replaces the conversation with the clinician who would be prescribing and monitoring you.

Questions worth asking your prescriber

• Which indication am I being prescribed under, and is this on-label or off-label for my situation?
• Can I realistically hold a 30-minute empty-stomach window every morning, given my other medications?
• What is the maintenance dose we are aiming for, and what will it cost me at that dose?
• Is the product being dispensed FDA-approved, or compounded?
• What monitoring and follow-up is included, and who do I contact if side effects escalate?

Keep comparing

• Alternatives: our Ozempic alternatives guide covers every FDA-approved option and the non-GLP-1 pills
• Every brand, one list: the GLP-1 medications list maps brand to molecule to approved indication
• Find a clinic: browse GLP-1 and weight-loss clinics by state